A federal judge ruled that the FDA lacks the statutory authority to regulate laboratory developed tests, finding squarely in favor of plaintiffs in the consolidated lawsuits brought by American Clinical Laboratories Association, Association for Molecular Pathology, and others. ASCP submitted an amicus brief supporting the plaintiffs.
Howard Hughes Medical Institute Investigator David R. Liu was awarded the 2025 Breakthrough Prize in Life Sciences for developing two gene-editing technologies—known as base editing and prime editing—which enable the correction or replacement of virtually any genetic mutation, including those that cause countless human genetic diseases.
Ira Mellman was named president of research at the Parker Institute for Cancer Immunotherapy.
Mark Cosentino has joined City of Hope as scientific director of the new Kathleen and Robert Henderson Biorepository, which is designed to be a best-in-class facility that collects and organizes tissue samples and other biological materials across City of Hope’s national system to further boost its cancer and other research.
Filippo Milano, a hematologist-oncologist and clinical researcher, was named the inaugural Endowed Chair in Cord Blood Research at Fred Hutchinson Cancer Center.
Dian Wang, William Tseng, and Brian A. Van Tine were appointed to NRG Oncology’s newly formed Sarcoma Subcommittee. Clifton (Dave) Fuller was named vice chair for NRG’s Imaging Committee.
Susan Leigh and Desirée A. H. Walker were awarded the National Coalition for Cancer Survivorship 2025 Ellen L. Stovall Award for Innovation in Patient-Centered Cancer Care.
Gabriele Casirati, of Boston Children’s Hospital, Susan E. De Wolf, of Memorial Sloan Kettering Cancer Center, Stephen Persaud, of Washington University School of Medicine, and Abdur Rehman, of the University of Texas MD Anderson Cancer Center, were awarded DKMS’ research grant in honor of John A. Hansen.
Researchers with Memorial Sloan Kettering and City of Hope have created a tool that uses machine learning to assess a non-Hodgkin lymphoma patient’s likely response to chimeric antigen receptor T-cell therapy before starting the treatment, according to study results published on April 1 in Nature Medicine.
A novel cell therapy approach using cord blood-derived natural killer cells pre-complexed with AFM13, or acimtamig, a CD30/CD16A bispecific antibody, was safe and generated strong response rates for patients with refractory CD30-positive lymphomas, according to a new study from the University of Texas MD Anderson Cancer Center.
